- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Amorfix received FDA Fast Track designation in Cambridge, MA.
1 report, 1 independent
Updated Sep 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Amorfix received FDA Fast Track designation in Cambridge, MA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Amorfix announced financing on July 28, 2025, from locations including Cambridge, MA and Toronto, Ontario.Sub-event
Amorfix was granted FDA Fast Track designation for its drug development.1 source
Keep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
-
Amorfix (Canada)
company in Mississauga, Canada
Nothing else this week.
- FDA
Related events
- A product was launched in the U.S. market following FDA involvement.
- FDA granted Fast Track designation to NRX-100 on September 4, 2025.
- Iovance Biotherapeutics listed its stock on Nasdaq and received Fast Track designation from the FDA.
- The FDA and European Medicines Agency discussed sharing the global regulatory leadership mantle.
- BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.
Coverage
Newest first; wire copies grouped- GlobeNewswireProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310 Cohort 2 fully enrolled; enrollment and dosing now underway for Cohort 3